These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 34633579)

  • 1. Chronological transition in outcome of second-line treatment in patients with metastatic urothelial cancer after pembrolizumab approval: a multicenter retrospective analysis.
    Isobe T; Naiki T; Sugiyama Y; Naiki-Ito A; Nagai T; Etani T; Nozaki S; Iida K; Noda Y; Shimizu N; Tomiyama N; Banno R; Kubota H; Hamamoto S; Ando R; Kawai N; Yasui T
    Int J Clin Oncol; 2022 Jan; 27(1):165-174. PubMed ID: 34633579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low Geriatric Nutritional Risk Index as a Poor Prognostic Marker for Second-Line Pembrolizumab Treatment in Patients with Metastatic Urothelial Carcinoma: A Retrospective Multicenter Analysis.
    Etani T; Naiki T; Sugiyama Y; Nagai T; Iida K; Noda Y; Shimizu N; Tasaki Y; Mimura Y; Okada T; Banno R; Kubota H; Hamamoto S; Ando R; Kawai N; Yasui T
    Oncology; 2020; 98(12):876-883. PubMed ID: 32862183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First Report of Oncological Outcome and Prognostic Analysis in a First-Line Setting of Short Hydration Gemcitabine and Cisplatin Chemotherapy for Patients with Metastatic Urothelial Carcinoma.
    Naiki T; Nagai T; Sugiyama Y; Etani T; Nozaki S; Iida K; Noda Y; Shimizu N; Isobe T; Matsumoto D; Kubota H; Hamamoto S; Ando R; Kawai N; Yasui T
    Oncology; 2021; 99(10):622-631. PubMed ID: 34284409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
    Powles T; Csőszi T; Özgüroğlu M; Matsubara N; Géczi L; Cheng SY; Fradet Y; Oudard S; Vulsteke C; Morales Barrera R; Fléchon A; Gunduz S; Loriot Y; Rodriguez-Vida A; Mamtani R; Yu EY; Nam K; Imai K; Homet Moreno B; Alva A;
    Lancet Oncol; 2021 Jul; 22(7):931-945. PubMed ID: 34051178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Skeletal Muscle Mass Reduction Velocity as a Simple Prognostic Indicator for Patients with Metastatic Urothelial Carcinoma Receiving Second-Line Chemotherapy.
    Nagai T; Naiki T; Iida K; Nozaki S; Etani T; Sugiyama Y; Ando R; Yanase T; Chaya R; Moritoki Y; Kobayashi D; Akita H; Okamura T; Yasui T
    Asian Pac J Cancer Prev; 2019 Oct; 20(10):2995-3000. PubMed ID: 31653146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GNRI Sustainability during One Cycle of First-Line Chemotherapy as a Prognostic Indicator in Patients with Metastatic Urothelial Carcinoma.
    Sugiyama Y; Naiki T; Tasaki Y; Mimura Y; Etani T; Noda Y; Nozaki S; Shimizu N; Banno R; Nagai T; Isobe T; Ando R; Moritoki Y; Kataoka T; Odagiri K; Aoki M; Gonda M; Yasui T; Hibi Y
    Oncology; 2023; 101(4):224-233. PubMed ID: 36689919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Rapidly Evolving Landscape of First-Line Targeted Therapy in Metastatic Urothelial Cancer: A Systematic Review.
    Lavoie JM; Sridhar SS; Ong M; North S; Alimohamed N; McLeod D; Eigl BJ
    Oncologist; 2021 Aug; 26(8):e1381-e1394. PubMed ID: 34028134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between comorbidities and survival in patients with metastatic urothelial carcinoma treated with pembrolizumab.
    Hashimoto M; Fukuokaya W; Yanagisawa T; Yamamoto S; Koike Y; Imai Y; Iwatani K; Onuma H; Ito K; Urabe F; Tsuzuki S; Kimura S; Oyama Y; Abe H; Miki J; Kimura T
    Int J Clin Oncol; 2024 May; 29(5):612-619. PubMed ID: 38430304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study).
    Bersanelli M; Buti S; Cortellini A; Bandini M; Banna GL; Pederzoli F; Farè E; Raggi D; Giannatempo P; De Giorgi U; Basso U; Losanno T; Santini D; Mucciarini C; Tucci M; Tambaro R; Farnesi A; Caffo O; Veccia A; Naglieri E; Briganti A; Procopio G; Pignata S; Necchi A
    Clin Med Insights Oncol; 2021; 15():11795549211021667. PubMed ID: 34290538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase II Study of Weekly Docetaxel as Second-Line Chemotherapy in Patients With Metastatic Urothelial Carcinoma.
    Kim YS; Lee SI; Park SH; Park S; Hwang IG; Lee SC; Sun JM; Lee J; Lim HY
    Clin Genitourin Cancer; 2016 Feb; 14(1):76-81. PubMed ID: 26454620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gemcitabine and docetaxel as second-line chemotherapy in elderly patients with metastatic urothelial carcinoma: a retrospective analysis.
    Naiki T; Iida K; Etani T; Nagai T; Tanaka Y; Sugiyama Y; Ando R; Hamamoto S; Banno R; Nagata D; Kawai N; Yasui T
    Cancer Manag Res; 2018; 10():3669-3677. PubMed ID: 30271215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pembrolizumab
    Takemura A; Matsushita Y; Tamura K; Sugiyama T; Nagata M; Otsuka A; Miyake H
    In Vivo; 2021; 35(3):1889-1894. PubMed ID: 33910878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nationwide Study of Real-World Treatment Patterns and Clinical Outcomes in Patients with Metastatic Urothelial Carcinoma in Hungary.
    Maráz A; Nagy B; Macher T; Jeskó J; Tischler E; Csongvai C; Kearney M
    Adv Ther; 2023 Dec; 40(12):5475-5488. PubMed ID: 37831384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response to Pembrolizumab After Dose-Reduced Cisplatin Plus Gemcitabine Chemotherapy Is Inferior to That After Carboplatin Plus Gemcitabine Chemotherapy in Cisplatin-Unfit Patients With Advanced Urothelial Carcinoma.
    Miyake M; Shimizu T; Nishimura N; Kiba K; Maesaka F; Oda Y; Tachibana A; Tomizawa M; Ohmori C; Matsumura Y; Ichikawa K; Mizobuchi S; Yoshikawa T; Hori S; Morizawa Y; Gotoh D; Nakai Y; Anai S; Torimoto K; Aoki K; Tanaka N; Fujimoto K;
    Clin Genitourin Cancer; 2022 Apr; 20(2):196.e1-196.e9. PubMed ID: 34916166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial.
    Nishiyama H; Yamamoto Y; Sassa N; Nishimura K; Fujimoto K; Fukasawa S; Yokoyama M; Enokida H; Takahashi K; Tanaka Y; Imai K; Shimamoto T; Perini R; Frenkl T; Bajorin D; Bellmunt J
    Int J Clin Oncol; 2020 Jan; 25(1):165-174. PubMed ID: 31729625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are there differences in the characteristics of patients who respond to gemcitabine plus cisplatin chemotherapy and those who respond to pembrolizumab therapy for metastatic urothelial carcinoma? Multicenter retrospective study.
    Shindo T; Maehana T; Tanaka T; Hashimoto K; Kobayashi K; Takahashi A; Hotta H; Kunishima Y; Taguchi K; Tachiki H; Ito N; Matsukawa M; Kato R; Miyamoto S; Hinotsu S; Masumori N
    Int J Urol; 2022 Sep; 29(9):1010-1016. PubMed ID: 35654444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-line Chemotherapy Response Is Associated With Clinical Outcome During Immune Checkpoint Inhibitor Treatment in Advanced Urothelial Carcinoma: A Real World Retrospective Study.
    Li JR; Wang SS; Lu K; Chen CS; Cheng CL; Hung SC; Chiu KY; Hsu CY; Yang CK
    Anticancer Res; 2023 Mar; 43(3):1331-1339. PubMed ID: 36854504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pembrolizumab Combined With Either Docetaxel or Gemcitabine in Patients With Advanced or Metastatic Platinum-Refractory Urothelial Cancer: Results From a Phase I Study.
    Parikh M; Pan CX; Beckett LA; Li Y; Robles DA; Aujla PK; Lara PN
    Clin Genitourin Cancer; 2018 Dec; 16(6):421-428.e1. PubMed ID: 30166228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic model in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitors after platinum failure.
    Park JH; Park I; Kim IH; Hur JY; Hwang I; Kim C; Kim HJ; Maeng CH; Park K; Lee MY; Lee HJ; Jung JY; Keam B; Park SH; Lee JL
    Curr Probl Cancer; 2022 Jun; 46(3):100848. PubMed ID: 35344842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of the fluctuation in the neutrophil-lymphocyte ratio at 6 weeks of pembrolizumab treatment is specific to the clinical response in metastatic urothelial carcinoma.
    Uchimoto T; Nakamura K; Komura K; Fukuokaya W; Yano Y; Nishimura K; Kinoshita S; Nishio K; Fukushima T; Nakamori K; Matsunaga T; Tsutsumi T; Tsujino T; Taniguchi K; Tanaka T; Uehara H; Takahara K; Inamoto T; Kimura T; Egawa S; Azuma H
    Urol Oncol; 2022 Jul; 40(7):344.e11-344.e17. PubMed ID: 35346572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.